Literature DB >> 22218908

Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.

Shunsuke Kondo1, Hidenori Ojima, Hitoshi Tsuda, Jun Hashimoto, Chigusa Morizane, Masafumi Ikeda, Hideki Ueno, Kenji Tamura, Kazuaki Shimada, Yae Kanai, Takuji Okusaka.   

Abstract

BACKGROUND: c-Met is an oncogene encoding a receptor for hepatocyte growth factor and, as such, plays a key role in hepatocellular carcinomas (HCC). We evaluated c-Met protein expression and its gene amplification in order to assess whether they were related to tumor recurrence and survival rates among patients who had undergone tumor resection.
METHODS: We used the polymer-based method to perform an immunohistochemistry analysis of c-Met expression on 59 formalin-fixed, paraffin-embedded sections of surgical specimens. c-Met gene amplification was investigated with fluorescence in-situ hybridization. Kaplan-Meier methods and Cox proportional hazards models were used to investigate relationships between c-Met expression, patient characteristics, tumor recurrence, and survival.
RESULTS: c-Met expression was associated with portal vein invasion (p = 0.006). Recurrence-free survival rates were significantly lower in patients with high levels of c-Met expression (p < 0.001). However, c-Met expression levels did not significantly affect overall survival rates (p = 0.12). Only 1 patient was found to have c-Met gene amplification; 22 patients were found to have aneuploidy of chromosome 7, on which the c-Met gene is located. Tumors with chromosome 7 polysomy tended to have higher levels of c-Met expression than those with chromosome 7 monosomy or disomy, but this difference was not statistically significant.
CONCLUSION: Although c-Met expression was not significantly associated with c-Met gene amplification, it may be a useful predictive marker of recurrence in resected HCC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22218908     DOI: 10.1007/s10147-011-0361-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  25 in total

1.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.

Authors:  M F Di Renzo; M Olivero; T Martone; A Maffe; P Maggiora; A D Stefani; G Valente; S Giordano; G Cortesina; P M Comoglio
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

2.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

3.  A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.

Authors:  S Chevret; J C Trinchet; D Mathieu; A A Rached; M Beaugrand; C Chastang
Journal:  J Hepatol       Date:  1999-07       Impact factor: 25.083

4.  A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma.

Authors:  F Donato; P Boffetta; M Puoti
Journal:  Int J Cancer       Date:  1998-01-30       Impact factor: 7.396

5.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Authors:  Pal Kaposi-Novak; Ju-Seog Lee; Luis Gòmez-Quiroz; Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

6.  c-met mRNA overexpression in human hepatocellular carcinoma.

Authors:  L Boix; J L Rosa; F Ventura; A Castells; J Bruix; J Rodés; R Bartrons
Journal:  Hepatology       Date:  1994-01       Impact factor: 17.425

Review 7.  Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Authors:  Paolo M Comoglio; Silvia Giordano; Livio Trusolino
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

8.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Authors:  F Cappuzzo; P A Jänne; M Skokan; G Finocchiaro; E Rossi; C Ligorio; P A Zucali; L Terracciano; L Toschi; M Roncalli; A Destro; M Incarbone; M Alloisio; A Santoro; M Varella-Garcia
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

9.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.

Authors:  W S Park; S M Dong; S Y Kim; E Y Na; M S Shin; J H Pi; B J Kim; J H Bae; Y K Hong; K S Lee; S H Lee; N J Yoo; J J Jang; S Pack; Z Zhuang; L Schmidt; B Zbar; J Y Lee
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

10.  Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Authors:  M F Di Renzo; M Olivero; A Giacomini; H Porte; E Chastre; L Mirossay; B Nordlinger; S Bretti; S Bottardi; S Giordano
Journal:  Clin Cancer Res       Date:  1995-02       Impact factor: 12.531

View more
  33 in total

1.  MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.

Authors:  Young Wha Koh; Yang-Soon Park; Hyo Jeong Kang; Ju Hyun Shim; Eunsil Yu
Journal:  Tumour Biol       Date:  2015-02-10

2.  Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Authors:  Nicola Personeni; Lorenza Rimassa; Tiziana Pressiani; Annarita Destro; Claudia Ligorio; Maria Chiara Tronconi; Silvia Bozzarelli; Carlo Carnaghi; Luca Di Tommaso; Laura Giordano; Massimo Roncalli; Armando Santoro
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-09       Impact factor: 4.553

Review 3.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

Review 4.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

5.  Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.

Authors:  Aloísio Felipe-Silva; Alda Wakamatsu; Cinthya Dos Santos Cirqueira; Venâncio Avancini Ferreira Alves
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

Review 6.  MET-dependent solid tumours - molecular diagnosis and targeted therapy.

Authors:  Robin Guo; Jia Luo; Jason Chang; Natasha Rekhtman; Maria Arcila; Alexander Drilon
Journal:  Nat Rev Clin Oncol       Date:  2020-06-08       Impact factor: 66.675

Review 7.  Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects.

Authors:  Seow Chong Lee; Hwee Tong Tan; Maxey Ching Ming Chung
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 8.  Update on biomarkers of hepatocellular carcinoma.

Authors:  Roongruedee Chaiteerakij; Benyam D Addissie; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2013-11-23       Impact factor: 11.382

Review 9.  HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.

Authors:  Jianjiang Fu; Xiaorui Su; Zhihua Li; Ling Deng; Xiawei Liu; Xuancheng Feng; Juan Peng
Journal:  Oncogene       Date:  2021-06-18       Impact factor: 9.867

10.  Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.

Authors:  Jie Sheng Chu; Fei Jiao Ge; Bo Zhang; Yan Wang; Nicola Silvestris; Lie Jun Liu; Chuan Hua Zhao; Li Lin; Anna Elisabetta Brunetti; Ya Li Fu; Jun Wang; Angelo Paradiso; Jian Ming Xu
Journal:  J Exp Clin Cancer Res       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.